Acacia to Seek $232 Million in London IPO for Drug Development

  • Medicines aim to treat nausea after surgery, chemotherapy
  • Stock expected to trade next month on London stock exchange

Acacia Pharma plans to raise about 150 million pounds ($232 million) by selling new shares in an initial public offering to fund the development of four medicines designed to quell post-surgery and post-chemotherapy symptoms such as vomiting for cancer patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.